Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer

International Journal of Molecular Medicine

Volumn 27, Issue 2, 2011, Pages 173-180

  Kan, On ^a   Day, Debbie ^a   Iqball, Sharifah ^a   Burke, Frances ^b   Grimshaw, Matthew J ^b,c   Naylor, Stuart ^a   Binley, Katie ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Hypoxia; Macrophage; P450

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL DESTRUCTION; CANCER SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DNA MODIFICATION; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYPOXIA; MACROPHAGE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANOXIA; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MACROPHAGES; MICE; MICE, NUDE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751659718     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.583     Document Type: Article

References (27)

1. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005.
2. Murdoch C, Muthana M and Lewis CE: Hypoxia regulates macrophage functions in inflammation. J Immunol 175: 6257-6263, 2005.
3. Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
4. Knowles HJ and Harris AL: Macrophages and the hypoxic tumour microenvironment. Front Biosci 12: 4298-4314, 2007.
5. Martinez FO, Sica A, Mantovani A and Locati M: Macrophage activation and polarization. Front Biosci 13: 453-461, 2008.
6. Negus RP, Stamp GW, Hadley J and Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723-1734, 1997.
7. Negus RP, Turner L, Burke F and Balkwill FR: Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63: 758-765, 1998.
8. Turner L, Scotton C, Negus R and Balkwill F: Hypoxia inhibits macrophage migration. Eur J Immunol 29: 2280-2287, 1999.
9. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
10. Andreesen R, Hennemann B and Krause SW: Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 64: 419-426, 1998.
11. Chiocca EA and Waxman DJ: Cytochrome p450-based gene therapies for cancer. Methods Mol Med 90: 203-222, 2004.
12. Portsmouth D, Hlavaty J and Renner M: Suicide genes for cancer therapy. Mol Aspects Med 28: 4-41, 2007.
13. Chen L, Yu LJ and Waxm DJ: Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 57: 4830-4837, 1997.
14. Chen L and Waxman DJ: Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8: 1405-1416, 2002.
15. Kan O, Kingsman S and Naylor S: Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2: 857-868, 2002.
16. Griffiths L, Binley K, Iqball S, et al: The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 7: 255-262, 2000.
17. Binley K, Iqball S, Kingsman A, Kingsman S and Naylor S: An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 6: 1721-1727, 1999.
18. Kan O, Griffiths L, Baban D, et al: Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 8: 473-482, 2001.
19. Boast K, Binley K, Iqball S, et al: Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 10: 2197-2208, 1999.
20. Vaupel PW: Oxygenation of solid tumours. In: Drug Resistance in Oncology. Teicher BA (ed). Marcel Dekker, New York, pp53-85, 1993.
21. Webb SD, Owen MR, Byrne HM, Murdoch C and Lewis CE: Macrophage-based anti-cancer therapy: modelling different modes of tumour targeting. Bull Math Biol 69: 1747-1776, 2007.
22. Bartholeyns J, Lopez M and Andreesen R: Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res 11: 1201-1204, 1991.
23. Braybrooke JP, Slade A, Deplanque G, et al: Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 11: 1512-1520, 2005.
24. Elbarghati L, Murdoch C and Lewis CE: Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology 213: 899-908, 2008.
25. Thomas C: Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, 1989.
26. Jounaidi Y, Chen C-S, Veal GJ and Waxman DJ: Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther 5: 541-555, 2006.
27. Sun L, Chen CS, Waxman DJ, Liu H, Halpert JR and Kumar S: Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Arch Biochem Biophys 458: 167-174, 2007.